Mon-Fri 9:00-18:00 CET+39 095 7211344info@vitasanlabs.com

Family · Pharmaceutical analytical standards

Ticagrelor

An antiplatelet medicine approved in Europe in 2010 to prevent heart attacks and strokes after an acute coronary syndrome. Unlike clopidogrel and prasugrel it acts directly, without needing activation by the liver, and its effect is reversible. This family brings together the active ingredient, pharmacopoeial impurities, metabolites, labelled standards, nitrosamines, other impurities and synthesis intermediates.

Did you know?Its structure was designed by modifying ATP, the molecule that carries energy in every cell of our body.

TicagrelorGo to the active ingredient →
TicagrelorActive ingredientTicagrelorCat. No. P-T112-001CAS 274693-27-5
Ticagrelor-d7Isotopically labelledTicagrelor-d7Cat. No. P-T112-013CAS 1265911-55-4

EDQM standards 3

The official European Pharmacopoeia standards for this family.

Reference substanceTicagrelor CRSEDQM code Y0002222Family Ticagrelor

Need a molecule you cannot find?

Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.